Here's the EXAMINE NEJM article:

https://www.nejm.org/doi/full/10.1056/NEJMoa1305889

There were ~2700 patients per group. Data below is for placebo on left and alogliptin on right. It lists the SoC agent, number of placebo pateints on SoC (% of placebo patients on SoC), number of alogliptin patients on SoC (% of alogliptin pateints on SoC). If you really want to dig into the details you can compare SoC in BETonMACE to EXAMINE. This is from Table 2 in the EXAMINE NEJM paper. There are some differences, but that is not too surprising.

Antiplatelet agents 2602 (97.1) 2630 (97.4)

- Aspirin 2433 (90.8) 2448 (90.6)

- Thienopyridine 2165 (80.8) 2155 (79.8)

Beta-blockers 2203 (82.2) 2208 (81.7)

Statins 2420 (90.3) 2446 (90.6)

Antidiabetic agents 2649 (98.9) 2676 (99.1)

- Insulin 812 (30.3) 793 (29.4)

- Metformin 1805 (67.4) 1757 (65.0)

- Thiazolidinediones 64 (2.4) 67 (2.5)

- Sulfonylureas 1237 (46.2) 1266 (46.9)

Calcium-channel blockers 611 (22.8) 586 (21.7)

Diuretics 1009 (37.7) 1005 (37.2)

Renin–angiotensin system–blocking agents 2210 (82.5) 2201 (81.5)